계명대학교 의학도서관 Repository

Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer

Metadata Downloads
Author(s)
Jong Gwang KimSang Kyun SohnHong Suk SongKi-Young KwonYoung Rok DoKyung Hee LeeMyung Soo HyunHun Mo RyooSung Hwa BaeKeon Uk ParkJin Ho BaekWon Sik LeeJoo Seop ChungGoon Jae ChoChang-Hak SohnJung Soon JangHo Young ChungWansik Yu
Publication Year
2007
Abstract
Purpose : Since a weekly administration of paclitaxel has demonstrated a sustained efficacy and more favorable toxicity profile than a 3-weekly administration for various solid tumors, the present study has conducted to evaluate the efficacy and safety of a combination regimen of weekly paclitaxel plus cisplatin in patients with advanced gastric cancer.
Patients and methods: Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxle 100mg/m2 plus cisplatine 35mg/m2 on days 1 and 8 based on a 3-week cycle.
Results : Fifty=-two patients were enrolled in the current study. Two complete responses and 17 partial responses were confirmed, giving an overall response rate of 36.5%, At a median follow-up of 8.5 months, the median time to progression and median overall survival was 6.0 and 10.8 months, respectively. Grade 3 neutropenia occurred in the patients, while no grade 4 neutropenia or febrile neutropenia was observed. The most Common non-hematologic toxicity was nausea(grade 1/2, 56.9%). There were no treatment-related deaths.
Conclusion : A weekly paclitaxel and cisplatin combination was found to be well-tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as an important first-line treatment option for advanced gastric cancer.
Department
Dept. of Internal Medicine (내과학)
Publisher
School of Medicine
Citation
Cancer Chemotherapy and Pharmacology, Vol.60(6) : 863-869, 2007
Type
Article
ISSN
0344-5704
DOI
10.1007/s00280-007-0433-8
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/35261
Authorize & License
  • AuthorizeOpen
  • EmbargoForever
Files in This Item:

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.